High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867090/
https://www.ncbi.nlm.nih.gov/pubmed/29392887
http://dx.doi.org/10.1111/jcmm.13551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867090/
https://www.ncbi.nlm.nih.gov/pubmed/29392887
http://dx.doi.org/10.1111/jcmm.13551

Ejemplares similares